Shigella O1 lipopolysaccharide (None commonly used)

Shigella O1 lipopolysaccharide is a complex glycolipid structure embedded in the outer membrane of Shigella O1 bacteria. It consists of three major parts: lipid A (responsible for endotoxic activity and anchoring the molecule in the membrane), a core oligosaccharide, and a distal O-antigen polysaccharide, which defines serotype specificity and immunogenicity. The O-antigen is crucial for evasion of the host immune system and for bacterial survival; altered or mutant forms impact chain length and virulence. Lipid A triggers strong inflammatory responses through TLR4, and the overall structure enables bacterial resistance to host defenses and antibiotics. Changes in the structure and modifications of lipid A and O-antigen can influence disease severity and resistance patterns. LPS has become a major target for vaccine development and therapeutics due to its pivotal role in pathogenicity and host immune activation. If you require a more granular breakdown for a particular O1 serotype (e.g. specific sugar structures in the O-antigen chain), those details are available in specialized NMR and glycan studies. There are no well-known abbreviations beyond "LPS" or "O-antigen", and its primary therapeutic relevance is in infectious disease rather than classical pharmacology.

Other names

Shigella O1 LPSShigella O1 O-antigen

Antibiotics: disruption or neutralization of LPS barrier function by binding lipid A component, resulting in bacterial death. Vaccines: induction of protective immune antibodies against O-antigen polysaccharide. Immunotherapeutics: potential for anti-inflammatory agents targeting LPS-induced signaling.